This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Are Options Traders Betting on a Big Move in Acadia Healthcare Stock?
by Zacks Equity Research
Investors need to pay close attention to (Ticker) stock based on the movements in the options market lately.
ACHCPositive Net Change
medical
Best Cheap Stocks Under $10 to Buy Now in July
by Benjamin Rains
One area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.
TOIPositive Net Change
medical
TransMedics Completes PAD Aviation Investment to Expand in Europe
by Zacks Equity Research
TMDX's PAD Aviation investment expands its OCS model into Europe, aiming to boost organ logistics, utilization and adoption.
TMDXNegative Net Change ISRGNegative Net Change WSTNegative Net Change GMEDNegative Net Change
medical medical-devices
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
PACBNegative Net Change ISRGNegative Net Change WSTNegative Net Change GMEDNegative Net Change
medical medical-devices
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
by Zacks Equity Research
Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.
IONSPositive Net Change BIIBNegative Net Change RAREPositive Net Change
biotechs medical pharmaceuticals
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
by Zacks Equity Research
PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin expansion plans.
PODDPositive Net Change IARTNegative Net Change GMEDNegative Net Change PAHCNegative Net Change
medical
Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset?
by Sridatri Sarkar
ICON trades below its five-year median, but weaker 2026 guidance, control issues and leverage keep the stock in wait-and-see territory.
ICLRNegative Net Change TMONegative Net Change IQVPositive Net Change
medical
CareDx Completes Naveris Acquisition and Expands Oncology Reach
by Zacks Equity Research
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CDNANegative Net Change ISRGNegative Net Change WSTNegative Net Change PACBNegative Net Change
medical medical-devices
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
by Ekta Bagri
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
LQDAPositive Net Change JNJPositive Net Change UTHRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is ALHC Stock Worth Buying After a Big Rally and Higher Forecasts
by Sridatri Sarkar
Alignment Healthcare's improved profits, raised 2026 outlook and stronger cash flow support the bull case, but its big rally and richer valuation raise the buy bar.
ALHCNegative Net Change MOHPositive Net Change SGRYPositive Net Change
medical